Abstract
In this issue of Blood, Armand et al report on a clinical trial of pembrolizumab, an immunoglobulin G4 anti-programmed cell death-1 (anti-PD-1) antibody, administered to patients as consolidation or maintenance therapy after autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL).
Cite
CITATION STYLE
APA
Karmali, R., & Gordon, L. I. (2019, July 4). Revving up the immune engine in cHL. Blood. American Society of Hematology. https://doi.org/10.1182/blood.2019001015
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free